Remgro facing investor pressure to unbundle Mediclinic
Investors argue Remgro should consider unbundling its stake in Mediclinic but CEO Jannie Durand says that's not on the cards right now
24 March 2022 - 09:41
While Remgro is steadily narrowing the gap between its market value and that of its underlying investments, investors are questioning whether unbundling its stake in hospital group Mediclinic might accelerate the value unlock for shareholders.
Like most investment holding companies Remgro, which is chaired by Johann Rupert, trades at a notable discount to its intrinsic net asset value (NAV), though it doesn’t have the same punitive head office costs and fee structures of some of its rivals, such as Patrice Motsepe’s African Rainbow Capital (ARC) Investments, which ordinarily justify such discounts...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.